At a glance
ClinicalIndex Comparison RecordN/ACompleted· 362 enrolled
Drug / intervention
beclomethasone dipropionatedrug
Likely dose
beclomethasone dipropionate 160 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-Ethnicity (SAPPHIRE)
In Brief
A clinical study evaluating beclomethasone dipropionate for Asthma. Completed, enrolled 362 participants across 1 site.
Detailed Summary
Inhaled corticosteroids (ICS) are considered first-line treatment for persistent asthma, yet little is known about the genetic factors that influence response to this therapy. This study seeks to quantify response to ICS therapy in African American and white patients, as well as look for genetic markers that predict treatment response.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2007
First PostedJun 2010
Primary CompletionFeb 2017
Study CompletionMar 2019
TodayJul 2026
First PostedJun 14, 2010
Enrollment StartOct 1, 2007
Primary CompletionFeb 1, 2017
Study CompletionMar 11, 2019
TodayJul 2, 2026
Enrollment to primary: 9.3 yearsPosted 16.1 years ago
Interventions
beclomethasone dipropionatedrug
160 mcg twice a day (320 mcg per day total)